$1.13
+0.00 (+0.00%)
Open$1.08
Previous Close$1.13
Day High$1.17
Day Low$1.08
52W High$4.98
52W Low$0.78
Volume—
Avg Volume876.0K
Market Cap143.73M
P/E Ratio—
EPS$-1.12
SectorBiotechnology
Analyst Ratings
Buy
12 analysts
Price Target
+1,631.9% upside
Current
$1.13
$1.13
Target
$19.57
$19.57
$11.03
$19.57 avg
$23.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 87.65M | 120.21M | 66.42M |
| Net Income | -153,636,249 | -189,648,366 | 9.87M |
| Profit Margin | -175.3% | -166.5% | 14.9% |
| EBITDA | -130,119,938 | -169,543,191 | 12.50M |
| Free Cash Flow | — | — | 3.90M |
| Rev Growth | -27.1% | -27.1% | +3.3% |
| Debt/Equity | 3.72 | 3.72 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |